XENERA-1: a Randomised Double-Blind Phase Ii Trial of Xentuzumab in Combination with Everolimus and Exemestane Versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer and Non-Visceral Disease
AuthID
P-00Y-MBE
P-00Y-MBE